Repare Therapeutics Inc. presented new data at the American Association of Cancer Research’s (AACR) 15th Annual Ovarian Cancer Research Symposium. The data highlighted the impact of alterations in FBXW7, PPP2R1A, and CCNE1 in patients with metastatic ovarian and endometrial cancers.
The analysis, based on approximately 2,000 patients, confirmed that ovarian and endometrial cancers with CCNE1 amplifications, FBXW7 or PPP2R1A mutations carry a poor prognosis. These findings underscore inherent chemotherapy resistance and a lack of treatment options for patients with these biomarkers.
Repare's lunresertib and camonsertib are being evaluated in the Phase 1 MYTHIC clinical trial for patients harboring these lunresertib-sensitizing biomarkers. The company anticipates reporting data from the MYTHIC dose expansion trial in the fourth quarter of 2024, which could offer new therapeutic approaches for this patient population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.